The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing-remitting (RR) and secondary progressive (SP)...

Celý popis

Podrobná bibliografie
Hlavní autoři: Coles, A, Cox, A, Le Page, E, Jones, J, Trip, SA, Deans, J, Seaman, S, Miller, D, Hale, G, Waldmann, H, Compston, D
Médium: Journal article
Jazyk:English
Vydáno: 2006